TSHA's Business Model
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.tayshagtx.com |
| CEO (Chief Executive Officer) | Sean Nolan |
| Number of Employees | |
| IPO date | September 24, 2020 |
TSHA Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 3000 Pegasus Park Drive |
| City | Dallas |
| State | TX |
| Phone | 214 612 0000 |
| Zip Code | 75247 |
| Other Identifiers | |
| CIK | 0001806310 |
| ISIN | US8776191061 |
| CUSIP | 877619106 |
| Open | 4.63 |
| Previous Close | 4.61 |
| Volume | 5.02 Mil. |
| Average Volume | 2.74 Mil. |
| Day’s Range | 4.37 – 4.715 |
| 52 Week Range | 1.05-6.02 |
| MA (50) | 4.7289 |
| MA (200) | 3.91358 |
| Market Cap | 1.07 Bil. |
| Shares Out. | 273.9 Mil. |
| Earnings Date | Mar 19, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
